TMCnet News

Glancy Prongay & Murray LLP Commences Investigation on Behalf of Halozyme Therapeutics, Inc. Investors (HALO)
[January 19, 2018]

Glancy Prongay & Murray LLP Commences Investigation on Behalf of Halozyme Therapeutics, Inc. Investors (HALO)


Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Halozyme Therapeutics, Inc. ("Halozyme" or the "Company") (NASDAQ: HALO) investors concerning the Company and its officers' possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the Halozyme investigation page on our website at www.glancylaw.com/case/halozyme-therapeutics-inc.



On January 16, 2018, an abstract was published detailing a study of Halozyme's drug PEGPH20 as a treatment for pancreatic cancer in combination with the cancer drug mFFOX. The abstract's authors concluded that the addition of PEGPH20 to mFFOX appears to be detrimental, noting that patients who used the combination experienced higher levels of diarrhea, fatigue, nausea, and vomiting. On this news, Halozyme's share price fell $1.76, or nearly 9%, to close at $17.98 on January 17, 2018, thereby injuring investors.

Follow us for updates on Twitter (News - Alert): twitter.com/GPM_LLP.


If you purchased Halozyme, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


[ Back To TMCnet.com's Homepage ]